Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of “Moderate Buy” by Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given a consensus rating of “Moderate Buy” by the ten analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $49.7778.

Several equities analysts have issued reports on the company. Wells Fargo & Company boosted their price target on Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a research note on Wednesday. The Goldman Sachs Group upped their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Monday, March 2nd. Wolfe Research raised Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target on the stock in a research note on Monday, March 23rd. Stifel Nicolaus reaffirmed a “buy” rating and set a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Monday, April 20th.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $31.34 on Tuesday. Celldex Therapeutics has a 52-week low of $18.55 and a 52-week high of $35.79. The business’s 50 day moving average price is $31.98 and its two-hundred day moving average price is $28.09. The firm has a market cap of $2.46 billion, a PE ratio of -7.36 and a beta of 0.98.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.80 million. Research analysts predict that Celldex Therapeutics will post -4.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Segall Bryant & Hamill LLC raised its stake in shares of Celldex Therapeutics by 36.3% in the third quarter. Segall Bryant & Hamill LLC now owns 528,597 shares of the biopharmaceutical company’s stock worth $13,675,000 after purchasing an additional 140,709 shares during the last quarter. Propel Bio Management LLC purchased a new stake in shares of Celldex Therapeutics in the third quarter worth approximately $4,010,000. American Century Companies Inc. raised its stake in shares of Celldex Therapeutics by 4.6% in the third quarter. American Century Companies Inc. now owns 815,560 shares of the biopharmaceutical company’s stock worth $21,099,000 after purchasing an additional 35,575 shares during the last quarter. Eventide Asset Management LLC raised its stake in shares of Celldex Therapeutics by 37.1% in the third quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company’s stock worth $48,096,000 after purchasing an additional 502,909 shares during the last quarter. Finally, Braidwell LP purchased a new stake in shares of Celldex Therapeutics in the third quarter worth approximately $15,307,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.